Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 6/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 6/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.33 |
| ▸ | CDK2 | P24941 | 4/20 | 0.33 |
| ▸ | SPR | P35270 | 3/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16766294 | 1.00 | CDC7 (0.33) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL16766859 | 0.99 | CDC7 (0.33) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL16766892 | 0.99 | CDC7 (0.33) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL16766249 | 0.97 | CDC7 (0.33) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL16766291 | 0.97 | CDC7 (0.33) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL16766796 | 0.93 | CDC7 (0.33) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL16766537 | 0.83 | CDC7 (0.32) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL16766453 | 0.82 | — | — | |
| SCHEMBL14343751 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL14343400 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388195-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-12 | — | — | US | disclosed |
| US-20150158882-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158882-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | CDC7 929/4885ROCK1 2779/4885DBF4 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.